
In order to attract global investors, AstraZeneca said it will directly list its ordinary shares on the New York Stock Exchange, in addition to its shares trading in the UK and Sweden.
To do so, the Anglo-Swedish pharmaceutical giant needs to replace its existing US listing of AstraZeneca American Depositary Receipts (ADRs) on the Nasdaq.